MedDataX Logo

Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA

NCT ID: NCT01139658

Last Updated: 2014-01-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1676 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-08-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Observational cohort study on the prevention of venous thromboembolic events after elective orthopaedic surgery for Total Knee Replacement or Total Hip Replacement iin patients treated with PRADAXA to evaluate the efficacy ant safety of Pradaxa in real-life conditions

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery

NCT00846807

Arthroplasty, Replacement Thromboembolism
COMPLETED

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

NCT01153698

Venous Thromboembolism Arthroplasty, Replacement
TERMINATED

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

NCT00306254

Venous Thrombosis
COMPLETED PHASE2

Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery

NCT00847301

Arthroplasty, Replacement Thromboembolism
COMPLETED

Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery

NCT00967447

Thromboembolism Arthroplasty, Replacement, Hip
TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

All comers

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients treated with Pradaxa undergoing surgery for Total Knee Replacement or Total Hip Replacement
2. Patients 18 years of age or older at the time of recruitment

Exclusion Criteria

1. Patients presenting contraindication to prescription of Pradaxa
2. Patients in whom long term Anti vitamin K treatment is indicated
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Boehringer Ingelheim Investigational Site 30

Angers, , France

Site Status

Boehringer Ingelheim Investigational Site 41

Arles, , France

Site Status

Boehringer Ingelheim Investigational Site 40

Beauvais, , France

Site Status

Boehringer Ingelheim Investigational Site 2

Berck, , France

Site Status

Boehringer Ingelheim Investigational Site 25

Bordeaux, , France

Site Status

Boehringer Ingelheim Investigational Site 45

Boulogne-sur-Mer, , France

Site Status

Boehringer Ingelheim Investigational Site 13

Bruay-la-Buissière, , France

Site Status

Boehringer Ingelheim Investigational Site 42

Cahors, , France

Site Status

Boehringer Ingelheim Investigational Site 50

Castelnau-le-Lez, , France

Site Status

Boehringer Ingelheim Investigational Site 36

Chantilly, , France

Site Status

Boehringer Ingelheim Investigational Site 35

Châteaubernard, , France

Site Status

Boehringer Ingelheim Investigational Site 10

Châteaubriant, , France

Site Status

Boehringer Ingelheim Investigational Site 9

Clinique Des Maussins-Paris, , France

Site Status

Boehringer Ingelheim Investigational Site 44

Dole, , France

Site Status

Boehringer Ingelheim Investigational Site 3

Dracy-le-Fort, , France

Site Status

Boehringer Ingelheim Investigational Site 46

Haguenau, , France

Site Status

Boehringer Ingelheim Investigational Site 33

Illkirch-Graffenstaden, , France

Site Status

Boehringer Ingelheim Investigational Site 23

La Roche-sur-Yon, , France

Site Status

Boehringer Ingelheim Investigational Site 22

Lannion, , France

Site Status

Boehringer Ingelheim Investigational Site 27

Le Blanc Menil, , France

Site Status

Boehringer Ingelheim Investigational Site 31

Le Port-Marly, , France

Site Status

Boehringer Ingelheim Investigational Site 21

Libourne, , France

Site Status

Boehringer Ingelheim Investigational Site 5

Lille, , France

Site Status

Boehringer Ingelheim Investigational Site 19

Lyon, , France

Site Status

Boehringer Ingelheim Investigational Site 47

Marcq En Bareuil, , France

Site Status

Boehringer Ingelheim Investigational Site 12

Mâcon, , France

Site Status

Boehringer Ingelheim Investigational Site 28

Mérignac, , France

Site Status

Boehringer Ingelheim Investigational Site 26

Morlaix, , France

Site Status

Boehringer Ingelheim Investigational Site 48

Nancy, , France

Site Status

Boehringer Ingelheim Investigational Site 7

Nancy, , France

Site Status

Boehringer Ingelheim Investigational Site 8

Nice, , France

Site Status

Boehringer Ingelheim Investigational Site 11

Paris, , France

Site Status

Boehringer Ingelheim Investigational Site 17

Paris, , France

Site Status

Boehringer Ingelheim Investigational Site 6

Paris, , France

Site Status

Boehringer Ingelheim Investigational Site 24

Perpignan, , France

Site Status

Boehringer Ingelheim Investigational Site 49

Ploemeur, , France

Site Status

Boehringer Ingelheim Investigational Site 14

Poissy, , France

Site Status

Boehringer Ingelheim Investigational Site 39

Pontarlier, , France

Site Status

Boehringer Ingelheim Investigational Site 43

Pringy, , France

Site Status

Boehringer Ingelheim Investigational Site 15

Reims, , France

Site Status

Boehringer Ingelheim Investigational Site 20

Rennes, , France

Site Status

Boehringer Ingelheim Investigational Site 53

Saint Colombe Les Viennes, , France

Site Status

Boehringer Ingelheim Investigational Site 52

Saint-Georges-de-Didonne, , France

Site Status

Boehringer Ingelheim Investigational Site 4

Saint-Grégoire, , France

Site Status

Boehringer Ingelheim Investigational Site 18

Saint-Priest-en-Jarez, , France

Site Status

Boehringer Ingelheim Investigational Site 32

Saint-Priest-en-Jarez, , France

Site Status

Boehringer Ingelheim Investigational Site 51

Saint-Saulve, , France

Site Status

Boehringer Ingelheim Investigational Site 37

Saumur, , France

Site Status

Boehringer Ingelheim Investigational Site 34

Semur-en-Auxois, , France

Site Status

Boehringer Ingelheim Investigational Site 1

Strasbourg, , France

Site Status

Boehringer Ingelheim Investigational Site 38

Toulouse, , France

Site Status

Boehringer Ingelheim Investigational Site 29

Tourcoing, , France

Site Status

Boehringer Ingelheim Investigational Site 16

Villeneuve-sur-Lot, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1160.102

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin
NCT03299296 UNKNOWN PHASE3
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
NCT00168818 COMPLETED PHASE3
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
NCT01184989 COMPLETED PHASE4
Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty
NCT01809054 COMPLETED PHASE4
Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux.
NCT00555438 COMPLETED PHASE4
ENhanced Recovery and ABbreviated LEngth of Anticoagulation for Thromboprophylaxis After Primary Hip Arthroplasty
NCT06611319 RECRUITING PHASE3
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00452530 COMPLETED PHASE3
Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching
NCT03483181 UNKNOWN
Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
NCT00371683 COMPLETED PHASE3
inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT
NCT06581965 RECRUITING PHASE4
Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty
NCT02379663 COMPLETED PHASE4
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
NCT00423319 COMPLETED PHASE3
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
NCT00331838 COMPLETED PHASE2
Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
NCT00398905 COMPLETED PHASE2
Echo-Doppler Assessment of the Occurrence of Asymptomatic DVT in Orthopedic Replacement Surgery Under Enoxaparin
NCT01354704 COMPLETED PHASE4
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
NCT01203098 COMPLETED PHASE2
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
NCT00657150 COMPLETED PHASE3
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
NCT00152971 COMPLETED PHASE3
Dose Ranging Study in Elective Total Hip Replacement Surgery
NCT00338897 COMPLETED PHASE2/PHASE3
Safety of DAbigatran and RIvaroxaban Versus NAdroparin in the Prevention of Venous Thromboembolism After Knee Arthroplasty Surgery
NCT01431456 COMPLETED PHASE3
Leiden Trial in Prevention of Post-Operative ThromboEmbolic Events
NCT02987946 COMPLETED NA
PROphylaxis in NOn Major Orthopaedic Surgery
NCT02401594 TERMINATED PHASE3
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
NCT01344954 COMPLETED PHASE2
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
NCT00541320 WITHDRAWN PHASE2
A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
NCT03891524 COMPLETED PHASE2